Toremifene


Triphenylethylene SERM (tamoxifen analog)

A chlorinated triphenylethylene SERM analog of tamoxifen; alternative SERM in postmenopausal breast cancer.

Abstract

Toremifene (2-[4-[(Z)-4-chloro-1,2-diphenyl-1-buten-1-yl]phenoxy]-N,N-dimethylethanamine; CAS 89778-26-7; molecular formula C26H28ClNO; molecular weight 405.96) is a triphenylethylene SERM developed at Orion Pharma (Finland) and approved by the FDA in 1997 under the trade name Fareston. The compound is a chlorinated analog of tamoxifen, sharing the triphenylethylene scaffold and tissue-selective ER modulation profile. Pharmacokinetic differences from tamoxifen include reduced CYP3A4-dependent metabolism (decreasing some drug-drug interaction potential) and a different metabolite spectrum (notably absent the highly active endoxifen analog of tamoxifen). Approved for metastatic breast cancer in postmenopausal women with ER-positive or ER-unknown tumors. Plasma half-life is approximately 5 days. Adverse events parallel tamoxifen including thromboembolism and hot flashes. Used as a tamoxifen alternative in clinical and research contexts.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph